1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment

• Christopher J Nirschl,
• Nesreen Ismail,
• Andres Salmeron,
• Zoe Steuert,
• Jenna M Sullivan,
• Heather R Brodkin,
• Daniel J Hicklin,
• Cynthia Seidel-Dugan,
• William M Winston,
• Yuka Lewis

Affiliations

Christopher J Nirschl

Aff2 grid.21107.350000000121719311ImmunologyJohns Hopkins School of Medicine Baltimore MD USA

Nesreen Ismail

1Werewolf Therapeutics, Cambridge, MA, United States

Andres Salmeron

Werewolf Therapeutics, Cambridge, MA, United States

Zoe Steuert

Werewolf Therapeutics, Watertown, MA, USA

Jenna M Sullivan

Werewolf Therapeutics, Watertown, MA, USA

Heather R Brodkin

Werewolf Therapeutics, Watertown, MA, USA

Daniel J Hicklin

Werewolf Therapeutics, Watertown, MA, USA

Cynthia Seidel-Dugan

Werewolf Therapeutics, Watertown, MA, USA

William M Winston

Werewolf Therapeutics, Watertown, MA, USA

Yuka Lewis

Werewolf Therapeutics, Watertown, MA, USA